Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1066439 | 0.86 | METAP1 (0.45) | PSMB8METAP1ATRCA1CA2 | |
| SCHEMBL9209481 | 0.86 | ATR (0.50) | PTPN1PSMB8METAP1ATRCA1 | |
| SCHEMBL5550034 | 0.82 | RXFP1 (0.53) | METAP1BRD9RXFP1MEN1NPC1 | |
| SCHEMBL9291277 | 0.81 | RXFP1 (0.41) | PTPN1METAP1BRD9RXFP1GAA | |
| SCHEMBL3039310 | 0.80 | MAPT (0.49) | PSMB8METAP1ATRCA1CA2 | |
| SCHEMBL23960291 | 0.79 | ATR (0.43) | PSMB8METAP1ATRCA1CA2 | |
| SCHEMBL1483110 | 0.79 | CA1 (0.42) | PSMB8METAP1ATRCA1CA2 | |
| SCHEMBL22774998 | 0.79 | CA1 (0.42) | PSMB8METAP1ATRCA1CA2 | |
| SCHEMBL6586802 | 0.78 | METAP1 (0.38) | PSMB8METAP1ATRCA1CA2 | |
| SCHEMBL10470286 | 0.77 | PTPN1 (0.56) | PTPN1MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119913577-A | High-efficiency Gao Zhengping-capacity nickel electroplating solution | 深圳市溢诚电子科技有限公司 | 2025-05-02 | — | — | CN | claimed |
| CN-118668266-A | Cyanide-free electroless gold plating solution applied to wafer | 深圳市溢诚电子科技有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-119913577-A | High-efficiency Gao Zhengping-capacity nickel electroplating solution | 深圳市溢诚电子科技有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-118668266-A | Cyanide-free electroless gold plating solution applied to wafer | 深圳市溢诚电子科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-115667255-A | Halogenated heteroaryl and other heterocyclic kinase inhibitors and uses thereof | 艾欧麦克斯治疗股份公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2022-01-06 | — | — | US | disclosed |
| US-11059832-B2 | HPK1 inhibitors and methods of using same | UNIVERSITY HEALTH NETWORK (CA) | 2021-07-13 | — | — | US | disclosed |
| EP-3322711-B1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIV HEALTH NETWORK (CA) | 2021-03-10 | — | — | EP | disclosed |
| US-20200190104-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2020-06-18 | — | — | US | disclosed |
| US-20180179221-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2018-06-28 | — | — | US | disclosed |
| EP-1299381-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| EP-1177178-B1 | HETEROCYCLICALLY SUBSTITUTED BENZIMIDAZOLES, THE PRODUCTION AND APPLICATION THEREOF | ABBOTT GMBH & CO KG (DE) | 2004-12-29 | — | — | EP | disclosed |
| CN-1496364-A | Substituted quinazoline derivatives and their use as inhibitors | — | 2004-05-12 | — | — | CN | disclosed |
| US-6696437-B1 | Heterocyclically substituted benzimidazoles, the production and application thereof | ABBOTT GMBH & CO. KG (DE) | 2004-02-24 | — | — | US | disclosed |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | US | disclosed |
| EP-1299381-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| CN-1353695-A | Heterocyclically substituted benzimidazoles, production and application thereof | BASF AG (DE) | 2002-06-12 | — | — | CN | disclosed |
| WO-2002000649-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
| CN-1117731-A | Heteroaromatic compounds with antipsychotic activity | WELLCOME FOUND (GB) | 1996-02-28 | — | — | CN | disclosed |
| WO-1994018196-A1 | HETEROAROMATIC COMPOUNDS WITH ANTIPSYCHOTIC ACTIVITY | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059832-B2 | HPK1 inhibitors and methods of using same | PDXK, PDK3, PDK2 | PTPN1 307/4885PSMB8 1842/4885METAP1 1137/4885 |
| US-20180179221-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | PDXK, PDK3, PDK2 | PTPN1 307/4885PSMB8 1842/4885METAP1 1137/4885 |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | PDXK, PDK3, PDK2 | PTPN1 328/4885PSMB8 1833/4885METAP1 1122/4885 |
| US-20200190104-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | PDXK, PDK3, PDK2 | PTPN1 307/4885PSMB8 1842/4885METAP1 1137/4885 |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKC, AURKB | PTPN1 2014/4885PSMB8 3125/4885METAP1 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.